Deciphering the therapeutic mechanisms of Fructus Ligustri Lucidi on diabetic nephropathy via bioinformatics analysis

doi:10.5246/jcps.2024.11.074

Abstract

Abstract:

This study aimed to investigate the potential mechanisms underlying the therapeutic effects of Fructus Ligustri Lucidi in the treatment of diabetic nephropathy (DN) through bioinformatics analysis. The research commenced with a comprehensive database search for DN-associated datasets and gene targets of Fructus Ligustri Lucidi. Subsequently, the ssGSEA method was employed to score the drug target gene sets, and based on these scores, subjects were categorized. Further analysis involved differential analysis and enrichment analysis techniques to elucidate differentially expressed genes (DEGs) and associated pathways between the two groups. Based on the ssGSEA scoring results, the data were stratified into two groups: the "High NZZ group" and the "Low NZZ group". Through differential analysis, a total of 18 DEGs were identified, comprising 14 upregulated genes (EGR1, CCL2, CDH6, VCAN-AS1, VCAN, C3, MMP7, RNASE6, C1QC, MOXD1, APOC1, SFRP2, CCL21, and LUM) and four downregulated genes (OTTHUMG00000152025, RERG, B3GALT2, and NELL1). Notably, several genes exhibited concurrent expression patterns in both the DN and High NZZ groups, including VCAN-AS1, CCL21, VCAN, MOXD1, CCL2, SFRP2, MMP7, C3, RNASE6, LUM, C1QC, APOC1, and CDH6. Enrichment analysis revealed significant enrichment in pathways related to "regulation of apoptotic cell clearance" and "granulocyte chemotaxis", among others. These findings highlighted the potential value of Fructus Ligustri Lucidi in the treatment of DN and unveiled novel potential targets for prognosis and therapy in DN patients. This study offered promising avenues for enhancing both the prognosis and treatment outcomes for individuals affected by this condition.

Key words: Diabetic kidney disease, Fructus Ligustri Lucidi, Bioinformatics, Data analysis

Supporting: /attached/file/20241214/20241214114423_929.pdf

Qinqing Li, Yanli Xin, Pulin Liu, Kaiwen Li, Caifang Jing, Xuelan Zhang, Wenbin He. Deciphering the therapeutic mechanisms of Fructus Ligustri Lucidi on diabetic nephropathy via bioinformatics analysis[J]. Journal of Chinese Pharmaceutical Sciences, 2024, 33(11): 1025-1039.

Figures/Tables 6

References 35

[1]	Zhong, Y.F.; Lee, K.; He, J.C. SIRT1 is a potential drug target for treatment of diabetic kidney disease. Front. Endocrinol. 2018, 9, 624.
[2]	Xue, R.; Gui, D.K.; Zheng, L.Y.; Zhai, R.N.; Wang, F.; Wang, N.S. Mechanistic insight and management of diabetic nephropathy: recent progress and future perspective. J. Diabetes Res. 2017, 2017, 1839809.
[3]	Sun, G.D.; Li, C.Y.; Cui, W.P.; Guo, Q.Y.; Dong, C.Q.; Zou, H.B.; Liu, S.J.; Dong, W.P.; Miao, L.N. Review of herbal traditional Chinese medicine for the treatment of diabetic nephropathy. J. Diabetes Res. 2016, 2016, 5749857.
[4]	de Boer, I.H.; Rue, T.C.; Hall, Y.N.; Heagerty, P.J.; Weiss, N.S.; Himmelfarb, J. Temporal trends in the prevalence of diabetic kidney disease in the United States. JAMA. 2011, 305, 2532–2539.
[5]	Jiang, G.Z.; Luk, A.O.Y.; Tam, C.H.T.; Xie, F.Y.; Carstensen, B.; Lau, E.S.H.; Lim, C.K.P.; Lee, H.M.; Ng, A.C.W.; Ng, M.C.Y.; Ozaki, R.; Kong, A.P.S.; Chow, C.C.; Yang, X.L.; Lan, H.Y.; Tsui, S.K.W.; Fan, X.D.; Szeto, C.C.; So, W.Y.; Chan, J.C.N.; Ma, R.C.W. Progression of diabetic kidney disease and trajectory of kidney function decline in Chinese patients with Type 2 diabetes. Kidney Int. 2019, 95, 178–187.
[6]	de Zeeuw, D.; Renfurm, R.W.; Bakris, G.; Rossing, P.; Perkovic, V.; Hou, F.F.; Nangaku, M.; Sharma, K.; Heerspink, H.J.L.; Garcia-Hernandez, A.; Larsson, T.E. Efficacy of a novel inhibitor of vascular adhesion protein-1 in reducing albuminuria in patients with diabetic kidney disease (ALBUM): a randomised, placebo-controlled, phase 2 trial. Lancet Diabetes Endocrinol. 2018, 6, 925–933.
[7]	Doshi, S.M.; Friedman, A.N. Diagnosis and management of type 2 diabetic kidney disease. Clin. J. Am. Soc. Nephrol. 2017, 12, 1366–1373.
[8]	Mauer, M.; Zinman, B.; Gardiner, R.; Suissa, S.; Sinaiko, A.; Strand, T.; Drummond, K.; Donnelly, S.; Goodyer, P.; Gubler, M.C.; Klein, R. Renal and retinal effects of enalapril and losartan in type 1 diabetes. N. Engl. J. Med. 2009, 361, 40–51.
[9]	Tang, G.Y.; Li, S.; Zhang, C.; Chen, H.Y.; Wang, N.; Feng, Y.B. Clinical efficacies, underlying mechanisms and molecular targets of Chinese medicines for diabetic nephropathy treatment and management. Acta Pharm. Sin. B. 2021, 11, 2749–2767.
[10]	Luan, R.Q.; Zhao, P.; Zhang, X.L.; Li, Q.Q.; Chen, X.F.; Wang, L. Pharmacodynamics, pharmacokinetics, and kidney distribution of raw and wine-steamed ligustri lucidi fructus extracts in diabetic nephropathy rats. Molecules. 2023, 28, 791.
[11]	Wang, H.; Huang, X.M.; Xu, P.F.; Liu, X.J.; Zhou, Z.H.; Wang, F.H.; Li, J.Y.; Wang, Y.H.; Xian, X.D.; Liu, G.; Huang, W. Apolipoprotein C3 aggravates diabetic nephropathy in type 1 diabetes by activating the renal TLR2/NF-κB pathway. Metabolism. 2021, 119, 154740.
[12]	Jiao, Y.Y.; Jiang, S.M.; Wang, Y.; Yu, T.Y.; Zou, G.M.; Zhuo, L.; Li, W.G. Activation of complement C1q and C3 in glomeruli might accelerate the progression of diabetic nephropathy: evidence from transcriptomic data and renal histopathology. J. Diabetes Investig. 2022, 13, 839–849.
[13]	Tang, S.M.; Wang, X.F.; Deng, T.C.; Ge, H.P.; Xiao, X.C. Identification of C3 as a therapeutic target for diabetic nephropathy by bioinformatics analysis. Sci. Rep. 2020, 10, 13468.
[14]	Jiao, Y.Y.; Jiang, S.M.; Wang, Y.; Yu, T.Y.; Zou, G.M.; Zhuo, L.; Li, W.G. Activation of complement C1q and C3 in glomeruli might accelerate the progression of diabetic nephropathy: evidence from transcriptomic data and renal histopathology. J. Diabetes Investig. 2022, 13, 839–849.
[15]	Wilkening, A.; Krappe, J.; Mühe, A.M.; Lindenmeyer, M.T.; Eltrich, N.; Luckow, B.; Vielhauer, V. C-C chemokine receptor type 2 mediates glomerular injury and interstitial fibrosis in focal segmental glomerulosclerosis. Nephrol. Dial. Transplant. 2020, 35, 227–239.
[16]	Feng, Y.; Zhong, X.; Ni, H.F.; Wang, C.; Tang, T.T.; Wang, L.T.; Song, K.Y.; Tang, R.N.; Liu, H.; Liu, B.C.; Lv, L.L. Urinary small extracellular vesicles derived CCL21 mRNA as biomarker linked with pathogenesis for diabetic nephropathy. J. Transl. Med. 2021, 19, 355.
[17]	Chang, T.T.; Chen, J.W. The role of chemokines and chemokine receptors in diabetic nephropathy. Int. J. Mol. Sci. 2020, 21, 3172.
[18]	Rayego-Mateos, S.; Morgado-Pascual, J.L.; Opazo-Ríos, L.; Guerrero-Hue, M.; García-Caballero, C.; Vázquez-Carballo, C.; Mas, S.; Sanz, A.B.; Herencia, C.; Mezzano, S.; Gómez-Guerrero, C.; Moreno, J.A.; Egido, J. Pathogenic pathways and therapeutic approaches targeting inflammation in diabetic nephropathy. Int. J. Mol. Sci. 2020, 21, 3798.
[19]	Moreno, J.A.; Gomez-Guerrero, C.; Mas, S.; Sanz, A.B.; Lorenzo, O.; Ruiz-Ortega, M.; Opazo, L.; Mezzano, S.; Egido, J. Targeting inflammation in diabetic nephropathy: a tale of hope. Expert Opin. Investig. Drugs. 2018, 27, 917–930.
[20]	Lu, J.; Chen, P.P.; Zhang, J.X.; Li, X.Q.; Wang, G.H.; Yuan, B.Y.; Huang, S.J.; Liu, X.Q.; Jiang, T.T.; Wang, M.Y.; Liu, W.T.; Ruan, X.Z.; Liu, B.C.; Ma, K.L. GPR43 activation-mediated lipotoxicity contributes to podocyte injury in diabetic nephropathy by modulating the ERK/EGR1 pathway. Int. J. Biol. Sci. 2022, 18, 96–111.
[21]	Dai, X.; Liao, R.Y.; Liu, C.Q.; Liu, S.; Huang, H.Y.; Liu, J.J.; Jin, T.R.; Guo, H.H.; Zheng, Z.H.; Xia, M.; Ling, W.H.; Xiao, Y.J. Epigenetic regulation of TXNIP-mediated oxidative stress and NLRP3 inflammasome activation contributes to SAHH inhibition-aggravated diabetic nephropathy. Redox Biol. 2021, 45, 102033.
[22]	Hirohama, D.; Abedini, A.; Moon, S.; Surapaneni, A.; Dillon, S.T.; Vassalotti, A.; Liu, H.B.; Doke, T.; Martinez, V.; Dom, Z.M.; Karihaloo, A.; Palmer, M.B.; Coresh, J.; Grams, M.E.; Niewczas, M.A.; Susztak, K. Unbiased human kidney tissue proteomics identifies matrix metalloproteinase 7 as a kidney disease biomarker. J. Am. Soc. Nephrol. 2023, 34, 1279–1291.
[23]	Ke, B.; Fan, C.; Yang, L.; Fang, X. Matrix metalloproteinases-7 and kidney fibrosis. Physiol. 2017, 8, 21.
[24]	Fu, H.Y.; Zhou, D.; Zhu, H.L.; Liao, J.L.; Lin, L.; Hong, X.; Hou, F.F.; Liu, Y.H. Matrix metalloproteinase-7 protects against acute kidney injury by priming renal tubules for survival and regeneration. Kidney Int. 2019, 95, 1167–1180.
[25]	Xu, Q.N.; Li, B.J.; Wang, Y.C.; Wang, C.L.; Feng, S.; Xue, L.; Chen, J.H.; Jiang, H. Identification of VCAN as hub gene for diabetic kidney disease immune injury using integrated bioinformatics analysis. Front. Physiol. 2021, 12, 651690.
[26]	Zhang, Y.; Ma, K.L.; Gong, Y.X.; Wang, G.H.; Hu, Z.B.; Liu, L.; Lu, J.; Chen, P.P.; Lu, C.C.; Ruan, X.Z.; Liu, B.C. Platelet microparticles mediate glomerular endothelial injury in early diabetic nephropathy. J. Am. Soc. Nephrol. 2018, 29, 2671–2695.
[27]	Yu, M.X.; Xie, R.J.; Zhang, Y.; Liang, H.; Hou, L.; Yu, C.Y.; Zhang, J.M.; Dong, Z.X.; Tian, Y.; Bi, Y.Y.; Kou, J.J.; Novakovic, V.A.; Shi, J.L. Phosphatidylserine on microparticles and associated cells contributes to the hypercoagulable state in diabetic kidney disease. Nephrol. Dial. Transplant. 2018, 33, 2115–2127.
[28]	van den Berg, B.M.; Wang, G.; Boels, M.G.S.; Avramut, M.C.; Jansen, E.; Sol, W.M.P.J.; Lebrin, F.; van Zonneveld, A.J.; de Koning, E.J.P.; Vink, H.; Gröne, H.J.; Carmeliet, P.; van der Vlag, J.; Rabelink, T.J. Glomerular function and structural integrity depend on hyaluronan synthesis by glomerular endothelium. J. Am. Soc. Nephrol. 2019, 30, 1886–1897.
[29]	Li, Y.J.; Chen, X.C.; Kwan, T.K.; Loh, Y.W.; Singer, J.; Liu, Y.Z.; Ma, J.; Tan, J.; Macia, L.; MacKay, C.R.; Chadban, S.J.; Wu, H.L. Dietary fiber protects against diabetic nephropathy through short-chain fatty acid-mediated activation of G protein-coupled receptors GPR43 and GPR109A. J. Am. Soc. Nephrol. 2020, 31, 1267–1281.
[30]	Lee, J.H.; Kim, D.; Oh, Y.S.; Jun, H.S. Lysophosphatidic acid signaling in diabetic nephropathy. Int. J. Mol. Sci. 2019, 20, 2850.
[31]	Xiao, H.M.; Sun, X.H.; Liu, R.B.; Chen, Z.Q.; Lin, Z.Y.; Yang, Y.; Zhang, M.; Liu, P.Q.; Quan, S.J.; Huang, H.Q. Gentiopicroside activates the bile acid receptor Gpbar1 (TGR5) to repress NF-kappaB pathway and ameliorate diabetic nephropathy. Pharmacol. Res. 2020, 151, 104559.
[32]	Madhusudhan, T.; Ghosh, S.; Wang, H.J.; Dong, W.; Gupta, D.; Elwakiel, A.; Stoyanov, S.; Al-Dabet, M.M.; Krishnan, S.; Biemann, R.; Nazir, S.; Zimmermann, S.; Mathew, A.; Gadi, I.; Rana, R.; Zeng-Brouwers, J.; Moeller, M.J.; Schaefer, L.; Esmon, C.T.; Kohli, S.; Reiser, J.; Rezaie, A.R.; Ruf, W.; Isermann, B. Podocyte integrin- β₃ and activated protein C coordinately restrict RhoA signaling and ameliorate diabetic nephropathy. J. Am. Soc. Nephrol. 2020, 31, 1762–1780.
[33]	Chen, X.W.; Tan, H.S.; Xu, J.; Tian, Y.; Yuan, Q.; Zuo, Y.Y.; Chen, Q.Y.; Hong, X.; Fu, H.Y.; Hou, F.F.; Zhou, L.L.; Liu, Y.H. Klotho-derived peptide 6 ameliorates diabetic kidney disease by targeting Wnt/β-catenin signaling. Kidney Int. 2022, 102, 506–520.
[34]	Sun, H.; Li, H.; Yan, J.; Wang, X.D.; Xu, M.Y.; Wang, M.X.; Fan, B.Z.; Liu, J.Y.; Lin, N.H.; Wang, X.; Li, L.; Zhao, S.T.; Gong, Y.F. Loss of CLDN5 in podocytes deregulates WIF1 to activate WNT signaling and contributes to kidney disease. Nat. Commun. 2022, 13, 1600.
[35]	Tang, S.C.W.; Yiu, W.H. Innate immunity in diabetic kidney disease. Nat. Rev. Nephrol. 2020, 16, 206–222.